Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 27:7:100157.
doi: 10.1016/j.lana.2021.100157. eCollection 2022 Mar.

Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs

Bishal Gyawali  1 , Laura M Carson  1 , Scott Berry  1 , Fabio Y Moraes  1
Affiliations

Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs

Bishal Gyawali et al. Lancet Reg Health Am. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflicts of interest associated to this work. FYM received honoraria from Astra Zeneca and IALSC outside the submitted work. FYM declares grants or contracts from CTAQ Queen's University outside the current work. FYM has received consulting fees from Cancer em foco outside of the submitted work. BG receives salary support from the Ontario Institute for Cancer Research funded by the government of Ontario. BG's work in Global Oncology is funded by the Conquer Cancer Foundation's Young Investigator Award in Global Oncology. Dr. Gyawali has received consulting fees from Vivio Health outside of the submitted work.

References

    1. Weigmann K. The ethics of global clinical trials. EMBO Rep. 2015;16(5):566–570. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428044/ Available at. Accessed 29 Jul 2021. - PMC - PubMed
    1. The Lancet Global Health Closing the door on parachutes and parasites. Lancet Glob Health. 2018;6(6):e593. doi: 10.1016/s2214-109x(18)30239-0. https://pubmed.ncbi.nlm.nih.gov/29773111/ (In eng)Available at. Accessed July 29 2021. - DOI - PubMed
    1. Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604. https://pubmed.ncbi.nlm.nih.gov/33581821/ Available at. Accessed July 29 2021. - PubMed
    1. Pai-Scherf L., Blumenthal G.M., Li H., Subramaniam S., Mishra-Kalyani P.S., He K., et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist. 2017;22(11):1392–1399. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679831/ Available at. Accessed Aug 30 2021. - PMC - PubMed
    1. United States Food & Drug Administration FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression. FDA. 2021 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro... Available at. Accessed Aug 3 2021.

LinkOut - more resources